Multiple myeloma is a cancer that affects a type of white blood cell called a plasma cell. Plasma cells produce antibodies to help fight infection and disease. In multiple myeloma, cancerous plasma ...

Multiple myeloma is considered to be relapsed if symptoms of the disease appear after a time of improvement. It’s considered to be refractory when it gets worse even though it’s being treated.

International Myeloma Foundation: “Multiple Myeloma and Anemia,” “Heart and Lung Complications.” Memorial Sloan Kettering Cancer Center: “Bone-Related Problems in Multiple Myeloma ...

Equecabtagene autoleucel showed high efficacy in relapsed/refractory multiple myeloma, with a 96% overall response rate and 42.6% complete response rate at three months. Minimal residual disease ...

Treatment with an experimental CAR-T therapy for multiple myeloma from Arcellx and Gilead Sciences resulted in zero cases of delayed neurotoxicity, including Parkinsonian symptoms and cranial ...

The Department of Veterans Affairs has started the process to designate multiple myeloma and acute and chronic leukemias as linked to military service in the Persian Gulf, Afghanistan and ...

The diagnosis of electrolyte imbalances (calcium, phosphorous, potassium and magnesium) in downer dairy cows often presents challenges. Treatment with electrolyte solutions such as calcium-phosphorous ...

The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J’s Carvykti, although Wall Street analysts were divided on how the two drugs compare. Carvykti ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead Sciences' Kite Pharma to treat relapsed or refractory multiple myeloma (RRMM). After seeing the data ...

Some users may not be comfortable with some of the additives in the pills, and it may not be as effective for people with severe electrolyte imbalances. Additionally, some users may prefer the ...